AIDS Research and Treatment

Clinical Study

Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality

Table 1

Predictors of treatment failure.
DeterminantTreatment Success*
𝑛 = 3 9 8 		Treatment Failure**
𝑛 = 3 3 7 		Univariate
( 𝑃 -value)		Multivariate
( 𝑃 -value)
Male gender
𝑛 (%)		 9 5 ( 2 4 ) 1 1 4 ( 3 4 ) < . 0 1 . 𝟎 𝟏
Mean Age (years) 3 5 . 3 3 5 . 3 1 . 0 —
Mean BMI ( k g / m 2 ) 2 1 . 1 1 9 . 9 < . 0 1 . 4
Karnofsky score
≤ 50 𝑛 (%)		 1 2 ( 3 ) 3 5 ( 1 1 ) < . 0 1 < . 0 1
Median CD4 ( c e l l s / m m 3 ) 8 4 5 4 < . 0 1 . 2
Mean 10log HIV-RNA 4 . 9 4 . 9 . 8 —
Time since start
ART 𝑛 (%)		 . 3 —
 (i) 2-3 years 2 1 7 ( 5 5 ) 1 6 2 ( 4 8 )
 (ii) 3-4 years 1 2 1 ( 3 0 ) 1 1 1 ( 3 3 )
 (iii) > 4 years 6 0 ( 1 5 ) 6 0 ( 1 8 )
Efavirenz use
𝑛 (%)		 2 2 3 ( 5 6 ) 2 0 4 ( 6 1 ) . 2 —
Stavudine use
𝑛 (%)		 3 2 4 ( 8 2 ) 2 5 3 ( 7 6 ) . 𝟎 𝟓 . 3
Unemployed
𝑛 (%)		 2 7 5 ( 7 4 ) 2 3 7 ( 7 9 ) . 1 —
Treatment success* patients who remained in care during followup and showed a good, virological response. Treatment failure**: a combined endpoint of patient attrition and virological failure. 𝑛 : number of patients. %: percentage of patients. BMI: body-mass index. CD4: CD4+ T-cell count. ART: antiretroviral treatment.